Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jan 11 2018

Hadassah’s Heart Institute: Innovation at the Forefront

Prof. Chaim Lotan, head of the Hadassah Medical Organization’s Heart Institute, has made it a personal objective to foster innovation in cardiovascular technology.

READ MORE ›
alt_text

Thursday, Jan 11 2018

Medical Clown Nehama’s Blog, Chapter Five: Out of Love

“I met Masha in the surgery waiting room at Hadassah Hospital Ein Kerem,” says Medical Clown Shira, as she proceeds to convey this story: Masha is a three-year-old girl who lives in Russia. Every three months, she comes to Hadassah for an oncological examination under full anesthesia.

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Bedridden Teen Walks Again, Thanks to First-in-Israel Complex Spinal Surgery at Hadassah

Yusef Rabaya, age 19, spent most of his life in bed at home in Jenin. Born with cerebral palsy (CP), he could sit only if he was propped up. Standing was excruciating and dangerous--and could cause permanent paralysis.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More